Want to see GDTC full AI Analyst Report?
GDTC Stock Chart & Stats
$1.39
-$0.41(-13.85%)
At close: 4:00 PM EST
$1.39
-$0.41(-13.85%)
Day’s Range― - ―
52-Week Range$0.68 - $3.68
Previous CloseN/A
Volume107.31K
Average Volume (3M)166.79K
Market Cap
$11.12M
Enterprise Value$14.85M
Total Cash (Recent Filing)$2.10M
Total Debt (Recent Filing)$482.56K
Price to Earnings (P/E)―
Beta0.07
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,832,835
10 Day Avg. Volume104,297
30 Day Avg. Volume166,789
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)3.07
Price to Sales (P/S)62.86
P/FCF Ratio-4.56
Enterprise Value/Market Cap1.34
Enterprise Value/Revenue23.10
Enterprise Value/Gross Profit-112.78
Enterprise Value/Ebitda-2.82
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Leverage And CapitalizationDebt-to-equity fell materially versus 2020–2022 and equity is sizable vs. assets in 2023–2025. A stronger capitalization profile reduces short-term refinancing pressure, lengthens runway for R&D and operations, and gives management more flexibility to execute strategy over the next several quarters.
Insider Alignment Via Chairman Share PurchasesThe chairman’s private acquisitions and stated intent to increase his stake indicate meaningful insider confidence and closer alignment with minority shareholders. That structural governance signal can support steadier strategic execution, improve board alignment on capital allocation, and lower agency risk over medium term.
Targeted R&D Funding For Subsidiary CapabilitiesA dedicated capital injection earmarked for a LongevityBank R&D lab expands internal innovation capacity and complements the existing cGMP facility. Strengthening in-house R&D and process capability is a structural move that can broaden the product pipeline and commercial readiness over multiple quarters.
Bears Say
Persistent Cash BurnOperating and free cash flow have been consistently negative and worsened in 2025, indicating reliance on external funding. Persistent cash burn constrains investment choice, forces dilutive financing or costly debt, and limits the firm’s ability to scale or sustain long-term R&D without new capital.
Consistent Losses And Deteriorating MarginsThe company has posted operating and net losses across periods and saw gross profit turn negative in 2025, signaling weakening unit economics. Persistent negative margins undermine eventual profitability prospects and increase the time and capital required to reach sustainable commercial returns.
Authorization To Issue New Shares (dilution Risk)Shareholder approval authorizing future share issuance creates a durable pathway for equity dilution. Given ongoing cash burn and losses, this structural authorization raises the probability of future equity financings, which can dilute existing holders and signals continued dependence on external capital.
CytoMed Therapeutics Limited News
GDTC FAQ
What was CytoMed Therapeutics Limited’s price range in the past 12 months?
CytoMed Therapeutics Limited lowest stock price was $0.68 and its highest was $3.68 in the past 12 months.
What is CytoMed Therapeutics Limited’s market cap?
CytoMed Therapeutics Limited’s market cap is $11.12M.
When is CytoMed Therapeutics Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were CytoMed Therapeutics Limited’s earnings last quarter?
Currently, no data Available
Is CytoMed Therapeutics Limited overvalued?
According to Wall Street analysts CytoMed Therapeutics Limited’s price is currently Overvalued.
Does CytoMed Therapeutics Limited pay dividends?
CytoMed Therapeutics Limited does not currently pay dividends.
What is CytoMed Therapeutics Limited’s EPS estimate?
CytoMed Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CytoMed Therapeutics Limited have?
CytoMed Therapeutics Limited has 11,832,835 shares outstanding.
What happened to CytoMed Therapeutics Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of CytoMed Therapeutics Limited?
Currently, no hedge funds are holding shares in GDTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CytoMed Therapeutics Limited
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells. Beyond its lead candidate, CytoMed is also advancing iPSC-gdNKT, which utilizes induced pluripotent stem cells (iPSCs) to generate a novel hybrid cell combining properties of both gamma delta T cells and natural killer cells. Additionally, the company is developing CTM-GDT, an immunotherapy consisting of expanded gamma delta T cells that leverages their innate, broad-spectrum recognition system to identify and address diverse cancer types.
Technical Analysis
Ownership Overview
34.84% Insiders
0.04% Mutual Funds
0.19% Other Institutional Investors
64.93% Public Companies and
Individual Investors